Japanese cedar and cypress family pollinosis
Conditions
Interventions
From the first medical examination, administer 5 mg as olopatadine hydrochloride twice a day orally in the morning and at bedtime , at least two weeks.
From the first medical examination, administe
Sponsors
Department of Otorhinolaryngology , Shiga University of Medical Science
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) It is pollinosis caused by Japanese cedar or cypress pollen and a final diagnosis is a done patient. (2) Patient judged that severity of symptoms when beginning to investigate is more than slight illness based on risk stratification of "Practical Guideline for the Management of Allergic Rhinitis in Japan(2009)" (3) Written informed consent is required.
Exclusion criteria
Exclusion criteria: (1) with nasal diseases such as nasal polyps, hypertrophic rhinitis, acute chronic rhinitis, or deviated septum which cause a barrier to evaluate nasal symptoms. (2) Patient that change of symptom is remarkable after specific immunotherapy is begun. (3) Patient who should continuously use medicine (antiallergic drugs, antihistamine drugs, anticholinergic drugs, a complex of histamine/ Gamma-globulin preparations, vasoconstrictor drugs and antihypertensive drugs) that influences when effect of drug evaluation. (5) Pregnancy, potential pregnancy, and breast-feeding patient. (6) the others, inappropriate to this study by the judgment of doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transitions of nasal symptom and ocular condition of two weeks after beginning of the treatment from first medical examination | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom score (stuffy nose,runny nose, sneezing,eye itchiness and tearing), medication score and QOL Questionaire score(JRQLQ No1). Satisfaction rating to treatment. | — |
Countries
Japan
Outcome results
None listed